MX2016007282A - Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico. - Google Patents

Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico.

Info

Publication number
MX2016007282A
MX2016007282A MX2016007282A MX2016007282A MX2016007282A MX 2016007282 A MX2016007282 A MX 2016007282A MX 2016007282 A MX2016007282 A MX 2016007282A MX 2016007282 A MX2016007282 A MX 2016007282A MX 2016007282 A MX2016007282 A MX 2016007282A
Authority
MX
Mexico
Prior art keywords
estrogen receptor
breast cancer
treatment
locally advanced
positive breast
Prior art date
Application number
MX2016007282A
Other languages
English (en)
Inventor
H Hager Jeffrey
Chen Isan
Chow Maneval Edna
F Roychowdhury Debasish
Tran H Truong Bao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016007282A publication Critical patent/MX2016007282A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen en la presente métodos para tratar cáncer de mama positivo al receptor de estrógenos localmente avanzado o metastásico.
MX2016007282A 2013-12-06 2014-12-05 Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico. MX2016007282A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361913167P 2013-12-06 2013-12-06
US201461981672P 2014-04-18 2014-04-18
PCT/IB2014/002679 WO2015082990A1 (en) 2013-12-06 2014-12-05 Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer

Publications (1)

Publication Number Publication Date
MX2016007282A true MX2016007282A (es) 2016-09-07

Family

ID=52347358

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007282A MX2016007282A (es) 2013-12-06 2014-12-05 Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico.

Country Status (12)

Country Link
US (2) US9675586B2 (es)
EP (1) EP3089747A1 (es)
JP (1) JP2016540767A (es)
KR (1) KR20160085915A (es)
CN (1) CN105916501A (es)
AU (1) AU2014358850A1 (es)
CA (1) CA2932106A1 (es)
HK (1) HK1223557A1 (es)
IL (1) IL245758A0 (es)
MX (1) MX2016007282A (es)
SG (1) SG11201604501TA (es)
WO (1) WO2015082990A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
JP2016517420A (ja) 2013-03-14 2016-06-16 セラゴン ファーマシューティカルズ， インク． 多環式エストロゲン受容体モジュレーター及びその使用
BR112015031903A8 (pt) 2013-06-19 2019-12-31 Seragon Pharmaceuticals Inc composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
WO2014205136A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
AU2015228860A1 (en) 2014-03-13 2016-09-08 F. Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
US20180173846A1 (en) * 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US9783503B2 (en) 2014-08-11 2017-10-10 Genentech, Inc. Crystalline forms of an estrogen receptor modulator
CN112375078B (zh) 2014-12-18 2023-12-19 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
CN107531722B (zh) 2015-05-26 2020-07-17 豪夫迈·罗氏有限公司 杂环雌激素受体调节剂及其用途
EP3359527A1 (en) 2015-10-07 2018-08-15 H. Hoffnabb-La Roche Ag Process for the preparation of (e)-3-(4-((e)-2-(2-chloro-4-fluorophenyl)-1-(1h-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid
US10519148B2 (en) 2015-11-12 2019-12-31 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
CA3017388C (en) 2016-04-01 2024-03-12 Zeno Royalties & Milestones, LLC Estrogen receptor modulators
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
AU2018287988A1 (en) * 2017-06-20 2019-10-10 Breast Cancer Now Methods and medical uses
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
UA129105C2 (uk) 2017-10-16 2025-01-15 Арагон Фармасьютикалз, Інк. Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози
EP3498273A1 (en) * 2017-12-14 2019-06-19 Universität Wien Pharmaceutical composition for modulating the response of a gaba-a receptor
EP3781714B1 (en) 2018-04-14 2026-01-07 Natera, Inc. Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna
PL3787632T3 (pl) * 2018-05-02 2022-07-18 Estetra Sprl Schemat leczenia dla leczenia zaawansowanego raka sutka z dodatnim receptorem estrogenowym
IL278063B2 (en) 2018-06-21 2025-08-01 Hoffmann La Roche Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
AR116299A1 (es) 2018-09-07 2021-04-21 Sanofi Sa Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas
BR112021022216A2 (pt) * 2019-05-09 2021-12-28 Sanofi Sa Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado
JP7736570B2 (ja) 2019-05-24 2025-09-09 浙江海正薬業股▲ふん▼有限公司 アクリル酸系誘導体の結晶形およびその調製方法及び用途
US11278532B2 (en) 2019-08-06 2022-03-22 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
CA3160897A1 (en) 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
JP2024502270A (ja) 2020-12-23 2024-01-18 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
EA201491530A1 (ru) 2012-03-20 2015-07-30 Серагон Фармасьютикалс, Инк. Модуляторы рецепторов эстрогенов и их применение
JP2016517420A (ja) 2013-03-14 2016-06-16 セラゴン ファーマシューティカルズ， インク． 多環式エストロゲン受容体モジュレーター及びその使用

Also Published As

Publication number Publication date
US20150157606A1 (en) 2015-06-11
CN105916501A (zh) 2016-08-31
CA2932106A1 (en) 2015-06-11
WO2015082990A8 (en) 2016-07-21
US20170239219A1 (en) 2017-08-24
US9675586B2 (en) 2017-06-13
HK1223557A1 (zh) 2017-08-04
IL245758A0 (en) 2016-07-31
AU2014358850A1 (en) 2016-06-16
AU2014358850A8 (en) 2016-08-04
JP2016540767A (ja) 2016-12-28
WO2015082990A1 (en) 2015-06-11
SG11201604501TA (en) 2016-07-28
EP3089747A1 (en) 2016-11-09
US10034860B2 (en) 2018-07-31
KR20160085915A (ko) 2016-07-18

Similar Documents

Publication Publication Date Title
MX2016007282A (es) Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico.
HUS2400002I1 (hu) Mellrák kezelése szelektív ösztrogénreceptor-módosítók alkalmazásával
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
PH12017501999A1 (en) K-ras modulators
IL245731A0 (en) Combined treatment for cancer
EP3180010A4 (en) Combination therapy for treating cancer
GEP20217331B (en) Anti-tigit antibodies
PT3063173T (pt) Anticorpos anti-cd38 específicos para o tratamento de cancros humanos
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
SG11201501653RA (en) Methods for the treatment of locally advanced breast cancer
PT3474841T (pt) Métodos de tratamento do cancro de mama ar+
IL244884B (en) Antibodies conjugated against ly75 for cancer therapy
EP3193884A4 (en) Combination therapy for treating cancer
MX2017007707A (es) Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.
PH12018502570B1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
TW201613587A (en) Medical treatments based on anamorelin
MX2015013021A (es) 5-bromo-indirrubinas.
EP3389670A4 (en) METHODS OF TREATING BREAST CANCER
EP3125878A4 (en) Methods of treating breast cancer
PH12018502571A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
GB201718806D0 (en) Breast cancer treatment
IN2013DE03375A (es)